{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(10)"],"submitter":["Bakesiima R"],"funding":["NORHED funded SURVIVAL-PLUSS Project"],"pubmed_abstract":["<h4>Objective</h4>To determine the prevalence and factors associated with dyslipidaemias in women using hormonal contraceptives.<h4>Design</h4>Cross-sectional study SETTING: Mulago Hospital, Kampala, Uganda PARTICIPANTS: Three hundred and eighty-four consenting women, aged 18-49 years, who had used hormonal contraceptives for at least 3 months prior to the study.<h4>Study outcome</h4>Dyslipidaemias (defined as derangements in lipid profile levels which included total cholesterol ≥200 mg/dL, high-density lipoprotein <40 mg/dL, triglyceride >150 mg/dL or low-density lipoprotein ≥160 mg/dL) for which the prevalence and associated factors were obtained.<h4>Results</h4>The prevalence of dyslipidaemias was 63.3% (95% CI: 58.4 to 68.1). Body mass index (BMI) (PR=1.33, 95% CI: 1.15 to 1.54, p<0.00"],"journal":["BMJ open"],"pagination":["e022338"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6196835"],"repository":["biostudies-literature"],"pubmed_title":["Dyslipidaemias in women using hormonal contraceptives: a cross sectional study in Mulago Hospital Family Planning Clinic, Kampala, Uganda."],"pmcid":["PMC6196835"],"pubmed_authors":["Tumwine JK","Najjingo I","Karamagi C","Nabaasa G","Byakika-Kibwika P","Nabaggala GS","Kalyango JN","Olweny F","Bakesiima R"],"additional_accession":[]},"is_claimable":false,"name":"Dyslipidaemias in women using hormonal contraceptives: a cross sectional study in Mulago Hospital Family Planning Clinic, Kampala, Uganda.","description":"<h4>Objective</h4>To determine the prevalence and factors associated with dyslipidaemias in women using hormonal contraceptives.<h4>Design</h4>Cross-sectional study SETTING: Mulago Hospital, Kampala, Uganda PARTICIPANTS: Three hundred and eighty-four consenting women, aged 18-49 years, who had used hormonal contraceptives for at least 3 months prior to the study.<h4>Study outcome</h4>Dyslipidaemias (defined as derangements in lipid profile levels which included total cholesterol ≥200 mg/dL, high-density lipoprotein <40 mg/dL, triglyceride >150 mg/dL or low-density lipoprotein ≥160 mg/dL) for which the prevalence and associated factors were obtained.<h4>Results</h4>The prevalence of dyslipidaemias was 63.3% (95% CI: 58.4 to 68.1). Body mass index (BMI) (PR=1.33, 95% CI: 1.15 to 1.54, p<0.00","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2026-06-06T20:37:32.768Z","creation":"2019-03-27T00:04:10Z"},"accession":"S-EPMC6196835","cross_references":{"pubmed":["30341126"],"doi":["10.1136/bmjopen-2018-022338"]}}